DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contributio
n

Tuesday, 13 December 2016

Dr.B Gopalan CSO & Executive Director, Drug Discovery Research, Orchid Chemicals and Pharmaceuticals Limited,

Image result for DR B GOPALAN



Gopalan B

Chief Scientific Officer,Drug Discovery Research, at Orchid Research Laboratories Limited,
 




 LINK

 http://182.73.176.174/chc/scientists/Dr_Gopalan.pdf

 https://in.linkedin.com/in/gopalan-b-b78b627


Dr.Balasubramanian Gopalan CSO & Executive Director, Drug Discovery Research, Orchid Chemicals and Pharmaceuticals Limited, Sholinganallur, Chennai.

Email: drbgopalan@yahoo.co.in

Dr.Balasubramanian Gopalan a Ph.D. in the year 1973 from University of Madras in Synthetic Organic Chemistry and worked as Post Doctoral fellow in Harvard University with Nobel laurite E.J.Corey and then switched over to the industry and joined Syntex Research Inc., California and Bristol-Myers Squibb in Newjersey, USA.

He returned to India in the year 1982 and headed drug discovery division of Boots Pharmaceuticals Ltd., Sun Pharma Advanced Research Centre, Glaxo Ltd., Glenmark Research Centre, Matrix Laboratories and finally join as Executive Director and Chief of Orchid Chemicals & Pharmaceuticals in the year 2008.

His achievements include discoveries of many new drugs that are in Phase-2 and Phase-3 clinical trial. Many of these discoveries such as Oglemilast (a novel PDE IV inhibitor) was out-licensed to Forest Laboratories, USA for US$190 million over a period of five years & also to Teijin of Japan for US$53 million.

Other of his drug melogliptin a new DPP4 for type 2 diabetes was out-licensed to Merck Germany for US$231 million.

He has been a visiting fellow and elected fellow of many academics and universities to his credit he has 50 international patents.

He shares his expertise by training local talents in drug discovery research from Orchid chemical & Pharmaceuticals Ltd., OMR, Chennai.

Education






University of Madras

ICOS21, IIT BOMBAY, DEC 2016

DR B GOPALAN, CSO & Executive Director,
Drug Discovery Research, Orchid Chemicals and
Pharmaceuticals Limited,Sholinganallur,Chennai.
 — with DR B GOPALAN, ORCHID.


////////////

No comments:

Post a comment